Our data show that loss of the KMT2C catalytic core motif, mimicking the scenario in patients, results in an enrichment of the proliferative MYC gene signature and impairs p16INK4A-mediated cell cycle arrest in both our model system and human prostate cancers. The gene discussed is CDKN2A; the disease is prostate carcinoma.